Own a piece of Neuralink
before it goes public.

A pre-IPO allocation of Neuralink shares, held through Binaryx. You choose your amount — from $250, at $245 / share (est.) — and realise value at a liquidity event: an IPO, an acquisition, or a secondary sale.

Up to 5% once at entry, and up to 20% of profit at exit — charged only on gains, never on your principal. Use the calculator above to see the full math on any amount.

Allocation is limited. This round has a fixed amount of Neuralink shares available. You can invest right away, but orders are filled in the order they're placed: first invest, first allocated. If the round fills before your order is reached, the amount we couldn't allocate is returned to your Binaryx balance automatically, so you're never charged for shares you don't receive.

The $245 / share price reflects Neuralink's current company valuation and is indicative. We'll always aim to secure you a better entry price. If the final price ends up more than 10% higher than shown, we refund your investment to your Binaryx balance, so you're never committed to a materially worse deal than advertised.

Think of it as a long-term investment: you're getting in early on a private company and growing with it toward an IPO, acquisition, or sale — so it suits money you can set aside for a few years. You're not locked in, either — once the allocation round closes, your tokens can be traded on the Binaryx P2P market, so you're free to sell to another investor whenever there's a buyer.

More flexible than a typical private investment. Once the allocation round closes, your tokens can be traded on the Binaryx P2P market, so you can sell to another investor whenever there's a buyer — no need to wait years for a final exit. How quickly you sell simply depends on demand at the time.

Buying shares in a late-stage private company before it lists on a public exchange — usually at a price below where the next round or an IPO is expected to price. You enter ahead of an IPO or acquisition and aim to benefit if the private valuation rises.

A public stock trades on an exchange and can be sold any day. A pre-IPO share is private — there's no public exchange, so it's a longer-term hold, typically 1–5 years to a full exit like an IPO, acquisition, or sale. On Binaryx you can still trade it peer-to-peer in the meantime, whenever there's a buyer.

From Neuralink's funding rounds and recent transactions between private investors on secondary venues. The $245 shown is an estimate of that level; the price you actually pay is fixed when the deal closes and can differ from the indicative figure.

Right of First Refusal. When a private share is sold, the company or its existing shareholders may have a window (often ~30 days) to buy it first at the agreed price. If they exercise it, the trade doesn't complete and your funds are returned; if they pass, it settles to you.

No. Pre-commercial companies like Neuralink reinvest everything into growth. Your return comes only from an increase in the company's valuation, realised at a liquidity event — not from dividends or interim payouts.

You keep your stake. An exit could still come through an acquisition, a later listing attempt, or a secondary sale to another private investor. But timing is unpredictable and an exit is never guaranteed — plan to hold for the long term.

Your return would be lower than the modeled scenario, or negative. Pre-IPO is venture-stage: if the company were to fail, the shares can lose all their value and you could lose your entire investment. Only commit capital you can afford to lock up — or lose.

It holds FDA Breakthrough Device designations and runs approved human trials, but doesn't yet have marketing approval. The modeled path — pivotal trial in 2026, PMA around 2027, launch around 2028 — is a scenario, and regulatory timelines can move in either direction.

26 people use the implant today; the first has lived with it for ~2.5 years. Early issues — like thread retraction in Patient 1 — were recovered through software. Longer-horizon durability data doesn't yet exist anywhere in the industry; it accrues with every implant-year, and Neuralink has the most of it.

Musk sets the vision and draws the capital; day-to-day execution sits with co-founder DJ Seo (President & COO) and CEO Jared Birchall. As at Tesla and SpaceX, sentiment around Musk can move private-market pricing in both directions.

Synchron, Paradromics, Precision Neuroscience and Blackrock Neurotech are all active — Synchron could reach a first approval with its less-invasive device. Neuralink's edge is bandwidth (1,024 electrodes), human scale (26 patients vs a handful) and capital ($1.3B+ — more than the field combined).

That's the 2026–27 test: high-volume implant production, near-automated R1 surgery, and a 4th-gen chip on Samsung's 4nm process (test chips H1 2027). These milestones are still ahead — and they're the catalysts the 2026–28 thesis is built on.

Pre-commercial companies raise repeatedly, so some dilution is expected. New rounds have also marked the valuation up — the $650M Series E priced at $9B, and secondary venues now imply ~$44B. Your share count stays fixed; the total share count grows.

Not yet — like most pre-commercial medtech. The valuation reflects the expected post-approval market rather than current sales; first commercial availability is modeled around 2028. Clinical results, in either direction, are what re-price it.